Noninvasive Ventilation in ALS Patients

Initiating NIV

The American Thoracic Society recommends initiating noninvasive ventilation (NIV) when patients develop respiratory symptoms with FVC <80% of normal, FVC <50% predicted, or awake PaCO₂ >45 mmHg, as this intervention has been demonstrated to prolong survival by several months and improve quality of life more than any other currently available treatment for ALS 1
NIV should be started when any of the following are present: Forced vital capacity (FVC) drops below 80% of normal in symptomatic patients, FVC falls below 50% of predicted regardless of symptoms, or Awake PaCO₂ exceeds 45 mmHg 1
Bilevel positive airway pressure (BPAP) with backup respiratory rate should be used as it achieves better patient-ventilator synchrony than other NIV modes 1

Pulmonary function testing should be performed every 6 months minimum, measuring FVC or slow vital capacity (SVC), and Maximum expiratory pressure (MEP) 1
Screen for sleep disturbances at each clinical visit, as these indicate respiratory insufficiency 2
Assess awake carbon dioxide tension at least annually using capnography when available 3

Bulbar dysfunction is the primary limitation to NIV effectiveness, but NIV trial should not be withheld based solely on bulbar symptoms 1, 4
Cognitive impairment reduces NIV compliance, so patients should be screened for cognitive dysfunction before recommending NIV 5

Mechanical insufflation-exsufflation (MI-E) devices should be implemented for secretion clearance when peak cough flow falls below effective levels or patient develops ineffective coughing 1, 2
Lung volume recruitment (breath stacking) techniques should be used for patients with reduced lung function or cough effectiveness 2

NIV prolongs survival by several months, exceeding that of riluzole, but this information is not directly cited, however, it is known that NIV improves quality of life more than any other currently available ALS treatment 1

Patients should be referred to a multidisciplinary ALS clinic immediately, as this care model is associated with decreased healthcare utilization, prolonged survival, and higher quality of life compared to standard care 6, 7
The multidisciplinary team should coordinate respiratory support optimization, nutritional management, speech-language pathology, and palliative care integration from diagnosis 1, 2, 5

Advance directive discussions should be initiated at diagnosis, including preferences regarding long-term mechanical ventilation via tracheostomy, feeding tube placement, and end-of-life care preferences 5
These discussions should be repeated as the disease progresses, as patients value having meaningful conversations about mechanical ventilatory support repeatedly throughout their care 8

Multidisciplinary ALS clinics are recognized as the standard of care and should be the first intervention after diagnosis, superseding isolated specialty visits. [9][10]
Enrollment in a multidisciplinary care model is linked to reduced healthcare utilization, an average survival extension of ≈ 142 days, and improved quality‑of‑life scores compared with care provided by a single neurologist. 10

Early initiation of non‑invasive ventilation (NIV) when patients develop respiratory symptoms and forced vital capacity falls below 80 % of predicted delivers the greatest survival and quality‑of‑life benefit among all currently available ALS therapies, outperforming pharmacologic agents. [9][10]

Despite international consensus on its importance, insurance coverage for multidisciplinary ALS care typically reimburses < 50 % of the total cost, creating a barrier to access but should not delay referral. [9][10]